What days are most likely to cause discomfort after taking Venetoclax/Venetoclax (Vekela) and how to relieve it

Venetoclax is a selective BCL-2 inhibitor mainly used to treat chronic lymphocytic leukemia (CLL) and other hematological malignancies. Discomfort is most likely to occur in the initial stage of medication, usually within the first 1 week, especially the first 3 to 5 days. This is because the drug promotes the lysis of tumor cells in a large amount in a short period of time, causing intracellular metabolites and substances such as potassium, phosphorus, and uric acid to be rapidly released into the blood, which may cause tumor lysis syndrome (TLS), manifested by symptoms such as fever, fatigue, nausea, vomiting, diarrhea, and muscle spasms.

In order to reduce the risk of discomfort, a gradual incremental dosing strategy is usually adopted clinically. The starting dose is low and gradually increased every week until the target dose is reached, which can help the body gradually adapt to the effects of the drug and reduce acute toxic reactions. At the same time, patients need to conduct hematology and electrolyte monitoring before and during medication, especially blood potassium, blood phosphorus, blood uric acid and renal function indicators, so that abnormalities can be detected and dealt with in a timely manner.

Methods to relieve discomfort include adequate hydration and symptomatic medication. While taking the drug, patients should ensure adequate daily fluid intake to help the kidneys excrete metabolites and reduce the risk of tumor dissolution. For mild to moderate discomfort, such as nausea, vomiting, or diarrhea, anti-nausea medications, antidiarrheal medications, or electrolyte supplements can be used under the guidance of a doctor. If there is a significant increase in serum potassium, serum phosphorus or serum uric acid, the drug dosage should be adjusted promptly or relevant drug intervention should be used, such as uric acid-lowering drugs or intravenous rehydration.

In addition, standardized follow-up and psychological preparation are also very important. Patients and their families should understand the possible symptoms of discomfort and their occurrence time, contact the doctor promptly when encountering abnormal symptoms, and should not stop taking the medicine or increase the dosage on their own. Through scientific increment, blood monitoring, hydration support and symptomatic treatment, most patients can safely get through the initial discomfort period of medication, thereby successfully completing the treatment plan of Venetoclax and achieving the best effect.

Reference materials:https://www.drugs.com/